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Managing Risk Factors for Atherosclerosis
in Critical Limb Ischaemia
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University of Lund, Department of Vascular Diseases, Malmo¨ University Hospital, S-205 02 Malmo¨, Sweden
Objective. To review the best medical management of critical limb ischaemia (CLI).
Methods. Published studies dealing with CLI and risk factors were searched for via PUBMED.
Findings and conclusions. Patients with critical limb ischaemia (CLI) have a one and ten year mortality of approximately
20% and 75% respectively. Risk factors for the development of peripheral atherosclerosis are the same as for coronary and
cerebrovascular atherosclerosis namely diabetes mellitus, hyperlipidaemia, arterial hypertension, and smoking. As there are
few studies of risk factor for peripheral arterial occlusive disease (PAOD), treatment recommendations are often based on
studies in patients with coronary or cerebrovascular atherosclerosis. While waiting for specific studies, CLI patients should
be treated according to current guidelines for other atherosclerotic patients.
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Smoking.Critical Limb Ischaemia, Cardiovascular
Disease, and Mortality
Critical limb ischaemia (CLI) is clinically defined as
chronic ischaemic rest pain, ulcers, or gangrene attrib-
utable to objectively proven arterial occlusive disease.1
For scientific purposes, the definition also includes an
ankle pressure of <50e70 mmHg, or toe pressure of
<30e50 mmHg, or TCPO2< 30e50 mmHg.
1 Patients
with CLI represent about 1% of the total number
of patients with peripheral arterial occlusive disease
(PAOD).1 Patients with PAOD and CLI usually have
extensive atherosclerotic disease in other arteries. A
high frequency of coronary heart disease,2,3 congestive
heart failure,3e5 and cardiac valve disease6 has been
demonstrated in patients with CLI. Between 50e70%
of patients with PAOD have symptoms or electrocar-
diographic signsof ischaemicheartdisease.4,5,7 Inanec-
ropsy study3 92% of patients requiring an amputation
for CLI showed advanced coronary atherosclerosis.
*Corresponding author. A. Gottsa¨ter, University of Lund,
Department of Vascular Diseases, Malmo¨ University Hospital,
S-205 02 Malmo¨, Sweden.
E-mail address: anders.gottsater@skane.se1078–5884/000478+ 06 $35.00/0  2006 Elsevier Ltd. All rights reA decreased ankle-brachial index is closely related to
both cardiovascular events and all-cause mortality.8,9
Total cardiovascular mortality is 3 to 5-fold increased
in PAOD patients compared with age-matched con-
trols.10e12 The one-year mortality in CLI is around
20%,13e15mainly as a result of cardiac events.15e17After
major vascular surgeryCLI patients have a 30-daymor-
tality of 5e6%.18 The 10-year survival rate in severe
symptomatic PAOD is as low as 25%.10
Risk Factors for Atherosclerosis in CLI
The risk factors for development of PAOD and CLI
are the same as for atherosclerosis in coronary and
cerebral vessels. In contrast to coronary and cerebral
atherosclerosis, however, there are few intervention
studies evaluating the effects of medical treatment of
risk factors for CLI. In order to provide recommenda-
tions for risk factor treatment, extrapolations from
intervention studies in patients with intermittent clau-
dication or coronary atherosclerosis are therefore
necessary. This review focuses upon five major
modifiable risk factors for CLI: diabetes mellitus, hy-
perlipidemia, arterial hypertension, platelet activity,served.
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were identified in 2005 through PubMed with the
search term ‘‘critical limb ischaemia’’ combined with
the different risk factors. In the absence of data on
CLI patients, articles on PAOD in general have been
used as references.
Diabetes mellitus
Diabetes mellitus is an important risk factor for PAOD
and CLI, also affecting the prognosis of the disease.
In the United Kingdom Prospective Diabetes Study
(UKPDS) of patients with type 2 diabetes, a 1% in-
crease in HbA1c was associated with a 28% increase
of the risk for development of PAOD during 6 years
of follow-up.19 Progression of CLI to gangrene occurs
in 40% of diabetic compared with 9% of nondiabetic
patients.20 In diabetic patients limb-salvage rate in
CLI has been reported to be lower21 and major ampu-
tation rate to be higher22 than in nondiabetic PAOD
patients. Diabetes is an independent risk factor for
postoperative amputation and complications23,24 and
has been found to predict hospital and long term mor-
tality in some25 but not all studies.15,24
Intensive glycaemic control decreases microvascu-
lar diabetic complications,26,27 but had no effects on
PAOD in the Diabetes Control and Complications Trial
(DCCT) in type 1 diabetes26 or upon amputation or
death from PAOD in the UKPDS in type 2 diabetes.27
Furthermore, in type 2 diabetic patients with estab-
lished macrovascular disease, pioglitazone treatment
has recently been shown to reduce the composite of
all-cause mortality, non-fatal myocardial infarction,
and stroke, whereas no significant effect was seen
on leg revascularisation or amputation.28 Treatment
goals for glycaemic control in diabetes are well
established. Current European recommendations29
(Table 1) propose target HbA1c 6.1% and target fast-
ing venous plasma glucose 6.0 mmol/l for patients
with type 2 diabetes mellitus. Whether such intensive
Table 1. Optimal target values according to current European
recommendations29 for medical treatment in patients with estab-
lished cardiovascular disease
Risk factors Treatment goal
Total cholesterol <4.5 mmol/l
LDL-cholesterol <2.5 mmol/l
Blood pressure <140/90 mmHg
In diabetic patients
Blood pressure <130/80 mmHg
HbA1c 6.1%
Fasting venous
plasma glucose
6.0 mmol/ltreatment favourably influences the prognosis for CLI
patients is not known.
Hyperlipidemia
Plasma levels of total and low-density lipoprotein
(LDL) cholesterol are important risk factors for coro-
nary heart disease.30 Although hyperlipidemia has re-
ceived considerably less attention as a risk factor in
PAOD than in coronary heart disease, there are several
indications of unfavourable effects of hyperlipidaemia
in PAOD. Hypertriglyceridaemia independently in-
creases the risk for progression of intermittent claudica-
tion to CLI31 and increased lipoprotein(a) levels are
associated with higher mortality in CLI.32 Lipid levels
should be evaluated with caution in CLI, however,
since they are often falsely low in this condition.33
Effects of lipid reduction have been studied in
PAOD. The Program On the Surgical Control of
Hyperlipidemias (POSCH) study,34 in which a 38%
reduction in LDL cholesterol was obtained by partial
ileal bypass, reported a reduction in PAOD and inter-
mittent claudication after 10 years follow-up. Statins
have beneficial effects on plaque stabilisation, platelet
adhesion, thrombosis, inflammation and endothelial
function.35 In the Scandinavian Simvastatin Survival
Study (4S)36 patients with ischaemic heart disease
treated with simvastatin showed a 38% risk reduction
for new or worsening intermittent claudication. Al-
though pravastatin does not affect femoral atheroscle-
rosis in primary prevention, it significantly reduces
the intima-media thickness of the common femoral ar-
tery in subjects with coronary artery disease.37 In the
Heart Protection Study38 treatment with simvastatin
was associated with a significant mortality reduction
in the 2701with PAOD. Statinsmaybe particularly ben-
eficial in patientswith increased inflammatorymarkers
and favourable influence walking ability, graft patency
and complications rates after revacularisation.39e43
Current European recommendations29 (Table 1)
propose targets for lipid lowering treatment in subjects
with established arterial disease, including PAOD, of
total cholesterol <4.5 mmol/l and LDL cholesterol
<2.5 mmol/l.
Arterial hypertension
Arterial hypertension is a prevalent risk factor in
PAOD and CLI. The frequency of arterial hypertension
in American outpatients with PAOD is reported to be
>80%.44 In European primary care patients with both
symptomatic and non-symptomatic PAOD,45,46 and
among American patients undergoing interventionsEur J Vasc Endovasc Surg Vol 32, November 2006
480 A. Gottsa¨terfor PAOD42 prevalences of arterial hypertension of
65e78% have been presented.
The Hypertension Optimal Treatment (HOT) trial47
showed that patients who reached diastolic blood
pressure (BP) 82.3 mmHg achieved maximum cardio-
vascular protection. Current European recommenda-
tions29 (Table 1) for antihypertensive treatment in
high risk subjects, including those with PAOD, pro-
pose target BP <140/90 mmHg in subjects without
diabetes, and <130/80 mmHg in subjects with diabe-
tes. Unfortunately, achievements of targets for BP con-
trol are low even in specialist centres.
ACE or angiotensin II inhibitors may have further
protective effects against cardiovascular events in
PAOD patients. In the Heart Outcome Prevention
Evaluation (HOPE) study48 44% of patients rando-
mised to ramipril 10 mg or placebo for 4e6 years
had PAOD, and ramipril was effective in reducing
vascular death, myocardial infarction, and stroke in
this subgroup, regardless of their ankle-brachial
index.9 Furthermore, the use of ACE-inhibitors is
also associated with lower mortality after infraingui-
nal bypass surgery.42 ß-blocking agents on the other
hand have previously been proposed to have un-
favourable effects upon symptoms in patients with
PAOD,49 and are underprescribed after myocardial
infarction among patients with PAOD, resulting in
increased mortality in this group.50 A meta-analysis51
has shown that ß-blockers do not adversely affect
walking capacity or symptoms of intermittent claudi-
cation in patients with mild to moderate PAOD, and
that no important differences in effects exist between
different types of ß-blockers in this context. Potentially
unfavourable effects of ß-blockers in more severely
ischaemic patients, such as those with CLI cannot
be excluded, however, since there are insufficiently
studies.51,52 Therefore, clinical observation of the peri-
pheral circulation is recommended when ß-blockers
are used in this group of patients.52 In our centre,
the blood pressure target for CLI patients is some-
times set above recommended levels29 in order to
increase perfusion to the ischaemic limb until ulcer
healing has occurred. This approach has not been
scientifically tested.
Antiplatelet treatment
Although no individual randomised trial has demon-
strated the efficacy of aspirin for reduction of cardio-
vascular events in PAOD, meta-analyses have shown
that antiplatelet agents reduce the risk of vascular
death, MI, and stroke by approximately 25% among
PAOD patients.53,54 Furthermore, aspirin therapy
significantly improves vascular graft patency afterEur J Vasc Endovasc Surg Vol 32, November 2006peripheral bypass surgery or angioplasty.55 European
recommendations propose treatment with aspirin or
other platelet modifying drugs in virtually all patients
with cardiovascular disease.29 In the CAPRIE study56
clopidogrel conferred an 8.7% further relative risk re-
duction for stroke, myocardial infarction, or vascular
death compared with aspirin among patients with
myocardial infarction, ischaemic stroke or PAOD.
Aspirin is still considered as first-line antiplatelet treat-
ment for patients with PAOD,57 even though a sub-
group analysis suggested that relative risk reduction
with clopidogrel was greater among PAOD patients
than among patients with myocardial infarction or
stroke in CAPRIE.56 Clopidogrel is recommended as
an alternative,58 when aspirin is contraindicated or
not tolerated. Clopidogrel might also be considered as
an alternative in patients with rapidly progressing dis-
ease or multiple events during aspirin therapy, but
as data are lacking no firm recommendations can be
made. To combine clopidogrel and aspirin is beneficial
in patients with acute coronary syndromes without
ST segment elevation,59 but not in those with recent
ischaemic stroke or transient ischaemic attack.60 Most
CLI patients have concomitant coronary artery
disease,2e5,7 but only a minority have a concomitant
acute coronary syndrome and combination treatment
can therefore not be generally recommended in CLI.
Smoking
Smoking is a major risk factor for both the occurrence
and progression of PAOD and CLI.1,20,61 The severity
of PAOD increases with the number of cigarettes
smoked,1 and continued smoking in PAODpatients in-
creases the risk for progression to CLI, amputation,
and the need for invasive intervention.62,63 Further-
more, continued smoking after leg revascularisation
negatively affects both patency rates61 and survival.64
Cessation of smoking, on the other hand, leads to
improved ankle pressure and exercise tolerance,65 im-
proved graft patency after surgery, and decreased risk
for fatal vascular complications66 in PAOD. The bene-
ficial effects of smoking cessation are evident within
a few years.67,68 Apart from the advise to quit smoking
that should be given to all CLI and PAOD patients, all
available forms of nicotine replacement therapy (such
as chewing gum, transdermal patch, nasal spray, inhaler
and sublingual tablets) have in a meta-analysis been
shown to increase the odds of successfully quitting
smoking approximately 1.5 to 2 fold regardless of
the additional support provided to the patient.69
Furthermore, a sustained release formulation of the
antidepressant bupropion can help relieve nicotine
abstinence symptoms.69,70
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in CLI Patients in Clinical Practise
While waiting for specific studies in CLI, these patients
should be treated according to current guidelines for
atherosclerotic patients.29 Recent studies have demon-
strated that risk factors for arteriosclerosis are often
suboptimally treated in PAOD patients,71,72 including
those with CLI.42,71,73,74 In spite of a recommended tar-
get Hba1c 6.1% in diabetes, a HbA1c <7% was seen
in only 52% of American outpatients with PAOD and
diabetes mellitus.72
After in-hospital care for invasive treatment of
PAOD, 50e60% of patients receive lipid-lowering
therapy.42,71 Among consecutive Swedish patients
with CLI, 24% were treated with lipid lowering drugs,
out of which 66% had reached target lipid levels.74
After invasive treatment of PAOD, 42e54% of
patients are treated with ACE-inhibitors42,71 and
58e69% with ß-blocking agents.42,71 In consecutive
Swedish CLI patients, the prevalence of BP lowering
treatment was <50%.74 Furthermore, mean BP levels
in patients with PAOD45,46 and CLI74 indicate that
many patients have not attained recommended levels
in spite of medical treatment.
Concerning antiplatelet and anticoagulant treat-
ment, awareness of and adherence to current guide-
lines29,57,58 seems to be better. Studies of consecutive
patients with CLI have shown that antiplatelet or
anticoagulant treatment are prescribed to 80e90% of
patients.42,69,74
Conclusion
Risk factors for arteriosclerosis and cardiovascular dis-
ease are common among patients with CLI. As there
are few studies of medical treatment in CLI patients,
extrapolation from studies in patients with other man-
ifestations of atherosclerosis are presently necessary to
provide treatment recommendations. Nevertheless,
medical risk-factor treatment in these high-risk pa-
tients is suboptimal in relation to current recommen-
dations. In order to decrease their high mortality and
morbidity from vascular disease, patients with CLI
need to be evaluated, treated, and scientifically stud-
ied by physicians with knowledge of and interest for
treatment of risk factors for atherosclerosis.
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